USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma, non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and inter-strand crosslinks that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or synergistic effects. Dianhydrogalactitol can be used for treatment of leptomeningeal carcinomatosis.雙脫水半乳糖醇之用途提供治療神經膠母細胞瘤、非小細胞肺癌(NSCLC)與卵巢癌,以及包括NSCLC腦轉移之其他類型惡性腫瘤之新穎治療模式。雙脫水半乳糖醇對DNA具有烷化劑之作用而產生N7甲基化與股間交聯,可誘發DNA之雙股斷裂。雙脫水半乳糖醇可有效抑制癌幹細胞之生長,針對替莫唑胺(temozolomide)、順鉑、與酪胺酸激酶抑制劑難治性腫瘤具活性;此藥物之作用與MGMT修復機制無關。雙脫水半乳糖醇可與其他抗腫瘤劑一起合用且可具加成或協同效應。雙脫水半乳糖醇可用於治療軟腦膜癌病。
